Institutional members access full text with Ovid®

Share this article on:

Management of Severe Allergic Conjunctivitis With Topical Cyclosporin A 0.05% Eyedrops

Ozcan, Altan A MD; Ersoz, T Reha MD; Dulger, Erol MD

doi: 10.1097/ICO.0b013e31812dfab3
Clinical Science

Purpose: To evaluate the efficacy of topical cyclosporin A 0.05% in the management of severe allergic conjunctivitis.

Methods: Seven patients with severe allergic conjunctivitis who were not responding to topical steroids, antihistamines, and mast cell stabilizers were given topical cyclosporin A 0.05%. All patients had an active disease when they were included in the study. Signs and symptoms were recorded before and after treatment.

Results: Seven patients, 6 boys and 1 girl, 6-14 years old, 6 with vernal keratoconjunctivitis and 1 with atopic keratoconjunctivitis, were enrolled in the study. Treatment with topical cyclosporin A 0.05% decreased the severity of symptoms and clinical signs significantly after 6 months (P < 0.05, Wilcoxon signed rank test). In addition, the need for steroids was reduced or even stopped. The patients experienced no side effects during the follow-up periods (mean, 14.0 ± 2.1 months; range, 8-18 months).

Conclusions: Topical cyclosporin A is an effective treatment in the management of severe allergic conjunctivitis with a benefit as a steroid-sparing agent.

From the Department of Ophthalmology, Çukurova University, Faculty of Medicine, Adana, Turkey.

Received for publication December 1, 2006; revision received May 11, 2007; accepted May 16, 2007.

The authors state that they have no proprietary interest in the products named in this article.

Reprints: Altan A. Ozcan, Cukurova University Medical Faculty, Department of Ophthalmology, 01330 Balcali, Adana, Turkey (e-mail:

© 2007 Lippincott Williams & Wilkins, Inc.